IBRANCE TABLET

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

PALBOCICLIB

Beszerezhető a:

PFIZER CANADA ULC

ATC-kód:

L01EF01

INN (nemzetközi neve):

PALBOCICLIB

Adagolás:

125MG

Gyógyszerészeti forma:

TABLET

Összetétel:

PALBOCICLIB 125MG

Az alkalmazás módja:

ORAL

db csomag:

15G/50G

Recept típusa:

Prescription

Terápiás terület:

ANTINEOPLASTIC AGENTS

Termék összefoglaló:

Active ingredient group (AIG) number: 0157970003; AHFS:

Engedélyezési státusz:

APPROVED

Engedély dátuma:

2019-10-31

Termékjellemzők

_IBRANCE (Palbociclib) – Product Monograph _
_Page 1 of 55_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
IBRANCE
®
Palbociclib
Capsules, 75 mg, 100 mg and 125 mg, oral
Tablets, 75 mg, 100 mg and 125 mg, oral
Protein Kinase Inhibitor
Pfizer Canada ULC
17300 Trans-Canada Highway
Kirkland, Quebec
H9J 2M5
Date of Initial Authorization:
MAR 15, 2016
Date of Revision:
MAR 07, 2024
Submission Control Number: 273901
®
Pfizer Inc.
Pfizer Canada ULC, Licensee
_ _
_IBRANCE (Palbociclib) – Product Monograph _
_Page 2 of 55_
RECENT MAJOR LABEL CHANGES
1 INDICATIONS
03/2024
4 DOSAGE AND ADMINISTRATION
03/2024
7 WARNINGS AND PRECAUTIONS
03/2024
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1
Dosing Considerations
............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.......................